Akoya Biosciences (Akoya Biosciences) Change In Receivables : $-0.91 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Akoya Biosciences Change In Receivables?

Akoya Biosciences's change in receivables for the quarter that ended in Mar. 2024 was $3.15 Mil. It means Akoya Biosciences's Accounts Receivable declined by $3.15 Mil from Dec. 2023 to Mar. 2024 .

Akoya Biosciences's change in receivables for the fiscal year that ended in Dec. 2023 was $-7.27 Mil. It means Akoya Biosciences's Accounts Receivable increased by $7.27 Mil from Dec. 2022 to Dec. 2023 .

Akoya Biosciences's Accounts Receivable for the quarter that ended in Mar. 2024 was $13.47 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Akoya Biosciences's Days Sales Outstanding for the three months ended in Mar. 2024 was 67.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Akoya Biosciences's liquidation value for the three months ended in Mar. 2024 was $-38.85 Mil.

Akoya Biosciences Change In Receivables Historical Data

The historical data trend for Akoya Biosciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akoya Biosciences Change In Receivables Chart

Akoya Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-3.37

6.70

-2.97

-0.29

-7.27

Akoya Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial													-3.21	0.08	-3.23	-0.90	3.15

Akoya Biosciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.91 Mil.

Akoya Biosciences (NAS:AKYA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Akoya Biosciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	13.473	/	18.35	*	91
=	67.00

2. In Ben Graham's calculation of liquidation value, Akoya Biosciences's accounts receivable are only considered to be worth 75% of book value:

Akoya Biosciences's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	61.575	-	122.027	+	0.75 * 13.473	+	0.5 * 22.988
=	-38.85

Akoya Biosciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Akoya Biosciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Akoya Biosciences (Akoya Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akoya Biosciences Inc (NAS:AKYA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Campus Drive, 6th Floor, Marlborough, MA, USA, 01752

Website

https://www.akoyabio.com

Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America.

Executives

Brian Mckelligon	director, officer: President/CEO	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Frederic Pla	officer: Chief Operating Officer	C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700
Goldman Myla Lai	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
John Frederick Ek	officer: Chief Financial Officer	5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel	director	5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Matthew Winkler	director	C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Thomas A. Raffin	director, 10 percent owner	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Robert G Shepler	director
Jennifer Kamocsay	officer: General Counsel	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762
Joseph Driscoll	officer: Chief Financial Officer	5 DICARLO ROAD, HOPKINTON MA 01748
Nolan Garry Ph.d.	director	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Thomas P Schnettler	director	800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Ehab El-gabry	officer: Chief Medical Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Marilee Moy	officer: Chief People Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Ramachandran Niro Ph.d	officer: Chief Business Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752